Home › Weight Loss Surgery › NCT04232566

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1

Who can join

Ages 30 to 70 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Undergoing gastric bypass surgery
* Confirmed AUROC F=0 or F\>2 liver fibrosis
* Age 30-70 years
* BMI greater than 40 kg/m2
* Negative pregnancy test (female only)
* Lab Values: Normal TSH

Exclusion Criteria:

* Autoimmune diseases
* Hepatitis B or C positive
* Heavy alcohol use
* Active smoking history
* Active cancer history
* History of asthma
* History of COPD
* Taking Plavix or Coumadin
* Blood donation within past 2 months
* Glucocorticoid Therapy
* Taking antihistamine on regular basis

About the study

This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.

What is being tested

• Bariatric surgery (procedure)

Sponsor: Mayo Clinic · Participants: 60 · Started: Feb 20, 2022

Contact the study team

• Keegan M Stewart · Phone: 480-301-4164

Official record on ClinicalTrials.gov — NCT04232566

Locations in the U.S.

Conditions

• Weight Loss Surgery
• Steatotic Liver Disease
• Obesity
• Insulin Resistance

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.